PABLO LUIS
ORTIZ ROMERO
Catedrático de universidad
University of Pittsburgh
Pittsburgh, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Pittsburgh (6)
2024
-
Maintenance therapy for CTCL: importance for prevention of disease progression
Leukemia and Lymphoma
2023
-
International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of cutaneous T-cell lymphoma outcomes during the COVID-19 pandemic: A retrospective cohort study
Journal of the American Academy of Dermatology, Vol. 88, Núm. 4, pp. 935-937
2021
-
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
European Journal of Cancer, Vol. 148, pp. 411-421
2017
-
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
The Lancet, Vol. 390, Núm. 10094, pp. 555-566
2016
-
Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB–IVA mycosis fungoides/Sézary syndrome
British Journal of Dermatology, Vol. 175, Núm. 1, pp. 80-88
2011
-
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Journal of Clinical Oncology, Vol. 29, Núm. 18, pp. 2598-2607